Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prostaglandin E1 in erectile dysfunction].

H Porst1

  • 1Urologische Abteilung Allgemeines Krankenhaus Harburg, Hamburg.

Der Urologe. Ausg. A
|March 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of prolonged scrotal drainage after penile prosthesis implantation: a multicenter prospective nonrandomized pilot study.

International journal of impotence research·2023
Same author

Physicians' attitudes towards androgen replacement therapy for male and female sexual dysfunction.

International journal of impotence research·2016
Same author

Results from an online survey investigating ED patients' insights and treatment expectations.

International journal of impotence research·2015
Same author

Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study.

International journal of clinical practice·2014
Same author

Genetic association study of the GNB3 C825T, the ACE I/D and the eNOS G894T polymorphisms and the risk to develop erectile dysfunction in a German ED population.

Andrologia·2010
Same author

[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].

Der Urologe. Ausg. A·2009
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Prostaglandin E1 (PGE1) injections effectively treat erectile dysfunction in most men, showing better results and fewer side effects like priapism compared to papaverine or papaverine/phentolamine combinations.

Area of Science:

  • Urology
  • Pharmacology
  • Andrology

Background:

  • Erectile dysfunction (ED) affects a significant number of men.
  • Intracavernous injections are a common treatment for ED.
  • Prostaglandin E1 (PGE1) is a potential therapeutic agent for ED.

Purpose of the Study:

  • To compare the efficacy and safety of PGE1 versus papaverine and papaverine/phentolamine for treating erectile dysfunction.
  • To evaluate the effectiveness of intracavernous PGE1 injections in achieving intercourse-adequate erections.

Main Methods:

  • A comparative study involving 249 patients with erectile dysfunction.
  • Administration of intracavernous injections of PGE1 (10 or 20 micrograms), papaverine, and papaverine/phentolamine.
  • Assessment of erection quality, duration of priapism, and patient-reported side effects.

Related Experiment Videos

Main Results:

  • PGE1 achieved intercourse-adequate erections in 72.3% of patients, significantly higher than papaverine (31.3%) or papaverine/phentolamine (60.3%).
  • PGE1 demonstrated a superior safety profile, with no cases of priapism lasting over 6 hours, unlike papaverine/phentolamine (5.2%).
  • 9.4% of patients experienced penile discomfort with PGE1, but self-injection therapy showed promising results.

Conclusions:

  • Intracavernous PGE1 is a highly effective and safe treatment for erectile dysfunction.
  • PGE1 offers significant advantages over papaverine and papaverine/phentolamine in terms of efficacy and reduced risk of priapism.
  • PGE1 is a valuable option for managing erectile dysfunction, with potential for successful self-administration.